CollPlant Biotechnologies Ltd.(CLGN)Earnings, Financials & Key Ratios
CLGN•NASDAQ
Price updated Jun 19, 2026
AboutCollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.Show more
- Revenue$2M+360.4%
- EBITDA-$11M+34.8%
- Net Income-$11M+30.8%
- EPS (Diluted)-0.94+35.2%
- Gross Margin26.32%+106.3%
- EBITDA Margin-445.85%+85.8%
- Operating Margin-484.31%+85.5%
- Net Margin-484.56%+85.0%
- ROE-117.56%-47.9%
CLGN Key Insights
CollPlant Biotechnologies Ltd. (CLGN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.7x book value
✗Weaknesses
- ✗Profits declining 14.8% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 7 (bottom 7%)
- ✗Sales declining 17.3% over 5 years
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CLGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CLGN Price & Volume
CollPlant Biotechnologies Ltd. (CLGN) stock price & volume — 10-year historical chart
Loading chart...
CLGN Growth Metrics
CollPlant Biotechnologies Ltd. (CLGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-17.32%
3 Years99.41%
TTM-84.26%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM5.28%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM15.57%
Return on Capital
10 Years-93.61%
5 Years-46.85%
3 Years-64.41%
Last Year-96.28%
CLGN Recent Earnings
CollPlant Biotechnologies Ltd. (CLGN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 2/12 qtrs (17%)
Q2 2026Latest
May 29, 2026Metric
Actual
Est
EPS
$0.23+3.1%
$0.24
Rev
$73,000-84.1%
$460,000
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$0.67-125.1%
$0.30
Rev
$60,000-97.1%
$2M
Q4 2025
Nov 26, 2025Metric
Actual
Est
EPS
$0.27-171.1%
$0.38
Rev
$77,000-98.9%
$7M
Q3 2025
Aug 20, 2025Metric
Actual
Est
EPS
$0.28-180.0%
$0.10
Rev
$179,000-98.9%
$17M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 29, 2026 | $0.23vs $0.24+3.1% | $73,000vs $460,000-84.1% |
| Q2 2026 | Mar 26, 2026 | $0.67vs $0.30-125.1% | $60,000vs $2M-97.1% |
| Q4 2025 | Nov 26, 2025 | $0.27vs $0.38-171.1% | $77,000vs $7M-98.9% |
| Q3 2025 | Aug 20, 2025 | $0.28vs $0.10-180.0% | $179,000vs $17M-98.9% |
Based on last 12 quarters of dataView full earnings history →
CLGN Peer Comparison
CollPlant Biotechnologies Ltd. (CLGN) competitors in Regenerative Medicine and Tissue Engineering — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RGEN | 7.45B | 132.02 | 153.51 | 16.36% | 6.73% | 2.46% | 0.33 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 AGIO | 2.03B | 34.16 | -4.80 | 48.03% | -6.4% | -34.11% | 0.05 | |
 ITGR | 3.13B | 90.96 | 31.47 | 7.57% | 7.67% | 8.23% | 0.80 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 OSUR | 305.85M | 4.25 | -4.52 | -38.1% | -61.93% | -15.09% | 0.04 | |
 MGRX | 3.33M | 0.33 | -0.16 | -25.96% | -46.33% | -120.72% | 0.02 | |
 ANIK | 193.24M | 14.42 | -18.97 | -5.91% | -9.52% | -7.74% | 0.17 |
Compare CLGN vs Peers
CollPlant Biotechnologies Ltd. (CLGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CLGN Income Statement
CollPlant Biotechnologies Ltd. (CLGN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 479.92K | 4.79M | 2.32M | 6.14M | 15.64M | 299K | 10.96M | 515K | 2.37M | 389K |
Revenue Growth % | 532.21% | 897.75% | -51.59% | 164.75% | 154.86% | -98.09% | 3565.22% | -95.3% | 360.39% | -84.26% |
Cost of Goods Sold | 306.09K | 1.9M | 1.88M | 3.46M | 2M | 1.48M | 3.09M | 2.66M | 1.75M | 1.63M |
COGS % of Revenue | 63.78% | 39.72% | 81.06% | 56.35% | 12.82% | 493.65% | 28.22% | 517.09% | 73.68% | - |
Gross Profit | 157.63K▲ 0% | 3.11M▲ 1874.2% | 439K▼ 85.9% | 2.68M▲ 510.3% | 13.64M▲ 409.0% | -1.18M▼ 108.6% | 7.87M▲ 768.3% | -2.15M▼ 127.3% | 624K▲ 129.1% | -1.24M▲ 0% |
Gross Margin % | 32.85% | 64.99% | 18.94% | 43.65% | 87.18% | -393.65% | 71.78% | -417.09% | 26.32% | -319.28% |
Gross Profit Growth % | 205.79% | 1874.22% | -85.89% | 510.25% | 409% | -108.63% | 768.31% | -127.31% | 129.05% | - |
Operating Expenses | 6.72M | 7.68M | 8.07M | 8.28M | 13.57M | 15.92M | 15.38M | 15.1M | 12.11M | 11.71M |
OpEx % of Revenue | 1400.44% | 160.47% | 348.15% | 134.89% | 86.77% | 5324.41% | 140.32% | 2932.62% | 510.63% | - |
Selling, General & Admin | 2.3M | 3.7M | 3.66M | 4.62M | 5.94M | 5.67M | 4.89M | 4.59M | 3.92M | 3.95M |
SG&A % of Revenue | 478.26% | 77.27% | 157.72% | 75.3% | 37.98% | 1894.65% | 44.66% | 890.87% | 165.33% | - |
Research & Development | 4.05M | 5.16M | 4.41M | 3.66M | 7.63M | 10.26M | 10.48M | 10.52M | 8.19M | 7.76M |
R&D % of Revenue | 843.29% | 107.8% | 190.42% | 59.59% | 48.79% | 3429.77% | 95.67% | 2041.75% | 345.3% | - |
Other Operating Expenses | 13.52K | 21.51K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -5.97M▲ 0% | -4.07M▲ 31.9% | -7.63M▼ 87.7% | -5.6M▲ 26.6% | 65K▲ 101.2% | -17.1M▼ 26403.1% | -7.51M▲ 56.1% | -17.25M▼ 129.6% | -11.48M▲ 33.4% | -12.95M▲ 0% |
Operating Margin % | -1244.18% | -84.91% | -329.21% | -91.23% | 0.42% | -5718.06% | -68.55% | -3349.71% | -484.31% | -3329.05% |
Operating Income Growth % | 16.62% | 31.91% | -87.7% | 26.63% | 101.16% | -26403.08% | 56.06% | -129.65% | 33.44% | - |
EBITDA | -5.68M | -3.72M | -7.09M | -4.94M | 838K | -16.02M | -6.41M | -16.21M | -10.57M | -12.07M |
EBITDA Margin % | -1183.42% | -77.76% | -305.95% | -80.48% | 5.36% | -5358.19% | -58.49% | -3148.16% | -445.85% | -3103.34% |
EBITDA Growth % | 18.11% | 34.44% | -90.46% | 30.36% | 116.97% | -2011.81% | 59.99% | -152.93% | 34.8% | 11.03% |
D&A (Non-Cash Add-back) | 291.63K | 342K | 539K | 660K | 773K | 1.08M | 1.1M | 1.04M | 912K | 878K |
EBIT | -5.7M | -6.22M | -11.09M | -5.74M | 274K | -16.89M | -7.01M | -16.59M | -11.48M | -12.93M |
Net Interest Income | -105.64K | -26K | -73K | -34K | 182K | 287K | 778K | 721K | 365K | -202K |
Interest Income | 0 | 0 | 0 | 0 | 219K | 321K | 788K | 738K | 380K | 24K |
Interest Expense | 105.64K | 26K | 73K | 34K | 37K | 34K | 10K | 17K | 15K | 226K |
Other Income/Expense | -94K | -2M | -3.53M | -175K | 172K | 172K | 493K | 642K | -6K | -184K |
Pretax Income | -6.01M▲ 0% | -3.69M▲ 38.6% | -11.16M▼ 202.8% | -5.77M▲ 48.3% | 237K▲ 104.1% | -16.93M▼ 7241.4% | -7.02M▲ 58.5% | -16.61M▼ 136.6% | -11.49M▲ 30.8% | -13.13M▲ 0% |
Pretax Margin % | -1251.8% | -77% | -481.62% | -94.09% | 1.52% | -5660.54% | -64.05% | -3225.05% | -484.56% | -3376.35% |
Income Tax | 28.44K | 2.96M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -0.47% | -80.15% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -5.8M▲ 0% | -6.25M▼ 7.7% | -11.16M▼ 78.7% | -5.77M▲ 48.3% | 237K▲ 104.1% | -16.93M▼ 7241.4% | -7.02M▲ 58.5% | -16.61M▼ 136.6% | -11.49M▲ 30.8% | -13.13M▲ 0% |
Net Margin % | -1209.56% | -130.5% | -481.62% | -94.09% | 1.52% | -5660.54% | -64.05% | -3225.05% | -484.56% | -3376.35% |
Net Income Growth % | 20.11% | -7.65% | -78.65% | 48.28% | 104.1% | -7241.35% | 58.53% | -136.63% | 30.83% | 5.28% |
Net Income (Continuing) | -6.05M | -6.25M | -11.16M | -5.77M | 237K | -16.93M | -7.02M | -16.61M | -11.49M | -13.13M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2.27▲ 0% | -1.43▲ 37.0% | -2.95▼ 106.3% | -0.84▲ 71.5% | 0.03▲ 104.1% | -1.52▼ 4544.4% | -0.62▲ 59.2% | -1.45▼ 133.9% | -0.94▲ 35.2% | -0.96▲ 0% |
EPS Growth % | 36.94% | 37% | -106.29% | 71.53% | 104.07% | -4544.44% | 59.21% | -133.87% | 35.17% | 15.57% |
EPS (Basic) | -2.27 | -1.43 | -2.95 | -0.84 | 0.04 | -1.52 | -0.62 | -1.45 | -0.94 | - |
Diluted Shares Outstanding | 2.66M | 4.38M | 4.99M | 6.89M | 11.97M | 11.03M | 11.39M | 11.45M | 12.2M | 13.75M |
Basic Shares Outstanding | 2.66M | 4.38M | 4.99M | 6.89M | 9.97M | 11.03M | 11.39M | 11.45M | 12.2M | 13.75M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CLGN Balance Sheet
CollPlant Biotechnologies Ltd. (CLGN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 6.45M | 7.14M | 5.04M | 5.68M | 45.09M | 31.66M | 28.02M | 13.18M | 6.75M | 5.54M |
Cash & Short-Term Investments | 5.13M | 5.33M | 3.79M | 3.33M | 43.3M | 29.65M | 26.67M | 11.91M | 5.95M | 4.26M |
Cash Only | 5.13M | 5.33M | 3.79M | 3.33M | 13.15M | 29.65M | 26.67M | 11.91M | 5.95M | 4.26M |
Short-Term Investments | 0 | 0 | 0 | 0 | 30.15M | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 102.02K | 516K | 79K | 830K | 270K | 9K | 393K | 583K | 1K | 233K |
Days Sales Outstanding | 77.59 | 39.33 | 12.44 | 49.36 | 6.3 | 10.99 | 13.09 | 413.19 | 0.15 | 142.86 |
Inventory | 201.4K | 810.37K | 888K | 1.26M | 1.08M | 1.43M | 714K | 440K | 573K | 679K |
Days Inventory Outstanding | 240.17 | 155.51 | 172.5 | 133.21 | 196.79 | 353.62 | 84.26 | 60.31 | 119.72 | 131.2 |
Other Current Assets | 525.21K | 380.01K | 136K | 93K | 437K | 566K | 241K | 248K | 223K | 365K |
Total Non-Current Assets | 1.62M | 1.91M | 5.71M | 5.17M | 6.14M | 6.11M | 6.1M | 5.53M | 4.04M | 3.64M |
Property, Plant & Equipment | 1.03M | 1.4M | 5.54M | 4.9M | 5.68M | 5.68M | 5.86M | 5.28M | 3.89M | 3.51M |
Fixed Asset Turnover | 0.47x | 3.42x | 0.42x | 1.25x | 2.75x | 0.05x | 1.87x | 0.10x | 0.61x | 0.10x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 418.35K | 338.01K | 0 | 82K | 243K | 245K | 188K | 131K | 73K | 59K |
Long-Term Investments | 171.39K | 173K | 168K | 181K | 0 | 188K | 57K | 118K | 76K | 417K |
Other Non-Current Assets | 171.19K | 172.06K | 0 | 181K | 426K | 188K | 0 | 0 | 0 | 0 |
Total Assets | 8.07M▲ 0% | 9.05M▲ 12.1% | 10.75M▲ 18.8% | 10.84M▲ 0.8% | 51.22M▲ 372.5% | 37.77M▼ 26.3% | 34.13M▼ 9.6% | 18.71M▼ 45.2% | 10.79M▼ 42.4% | 9.18M▲ 0% |
Asset Turnover | 0.06x | 0.53x | 0.22x | 0.57x | 0.31x | 0.01x | 0.32x | 0.03x | 0.22x | 0.03x |
Asset Growth % | 115.05% | 12.15% | 18.81% | 0.83% | 372.5% | -26.27% | -9.64% | -45.17% | -42.36% | -160.58% |
Total Current Liabilities | 1.42M | 2.23M | 3.46M | 3.39M | 3.01M | 3.1M | 3.25M | 2.97M | 2.67M | 2.44M |
Accounts Payable | 840.72K | 622K | 833K | 798K | 1.03M | 1.13M | 980K | 870K | 610K | 635K |
Days Payables Outstanding | 1K | 119.36 | 161.81 | 84.23 | 188.23 | 280.18 | 115.65 | 119.25 | 127.45 | 136.18 |
Short-Term Debt | 0 | 22K | 24K | 0 | 0 | 0 | 0 | 0 | 814K | 0 |
Deferred Revenue (Current) | 0 | 965.43K | 942K | 207K | 32K | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 574.29K | 44.45K | 245K | 1.27M | 566K | 499K | 1.54M | 1.19M | 1.25M | 0 |
Current Ratio | 4.56x | 3.19x | 1.46x | 1.68x | 14.96x | 10.20x | 8.62x | 4.44x | 2.53x | 2.27x |
Quick Ratio | 4.42x | 2.83x | 1.20x | 1.30x | 14.60x | 9.74x | 8.40x | 4.29x | 2.31x | 1.99x |
Cash Conversion Cycle | -684.77 | 75.48 | 23.12 | 98.34 | 14.86 | 84.43 | -18.3 | 354.26 | -7.58 | 137.88 |
Total Non-Current Liabilities | 4.04M | 2.05M | 3.21M | 2.98M | 3.09M | 2.38M | 2.54M | 2.27M | 2.03M | 1.85M |
Long-Term Debt | 3.64M | 22K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 3.14M | 2.95M | 3.09M | 2.38M | 2.54M | 2.27M | 2.03M | 8.23M |
Deferred Tax Liabilities | 0 | 742.66K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 404.25K | 1.08M | 68K | 28K | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 5.46M | 4.29M | 6.66M | 6.36M | 6.1M | 5.49M | 5.79M | 5.25M | 4.7M | 4.3M |
Total Debt | 3.64M | 44.61K | 3.62M | 3.39M | 3.61M | 2.91M | 3.16M | 3.08M | 2.85M | 2.65M |
Net Debt | -1.49M | -5.28M | -173K | 55K | -9.54M | -26.74M | -23.52M | -8.83M | -3.1M | -1.61M |
Debt / Equity | 1.39x | 0.01x | 0.89x | 0.76x | 0.08x | 0.09x | 0.11x | 0.23x | 0.47x | 0.54x |
Debt / EBITDA | - | - | - | - | 4.31x | - | - | - | - | -0.22x |
Net Debt / EBITDA | - | - | - | - | -11.38x | - | - | - | - | 0.13x |
Interest Coverage | -53.95x | -239.35x | -151.93x | -168.82x | 7.41x | -496.79x | -700.90x | -976.00x | -765.53x | -57.19x |
Total Equity | 2.61M▲ 0% | 4.76M▲ 82.1% | 4.09M▼ 14.1% | 4.48M▲ 9.5% | 45.12M▲ 907.8% | 32.28M▼ 28.5% | 28.34M▼ 12.2% | 13.46M▼ 52.5% | 6.08M▼ 54.8% | 4.89M▲ 0% |
Equity Growth % | 94.82% | 82.13% | -14.11% | 9.52% | 907.84% | -28.46% | -12.21% | -52.49% | -54.84% | -200.1% |
Book Value per Share | 0.98 | 1.09 | 0.82 | 0.65 | 3.77 | 2.93 | 2.49 | 1.18 | 0.50 | 0.36 |
Total Shareholders' Equity | 2.61M | 4.76M | 4.09M | 4.48M | 45.12M | 32.28M | 28.34M | 13.46M | 6.08M | 4.89M |
Common Stock | 1.44M | 1.52M | 2.37M | 2.93M | 4.66M | 4.87M | 4.98M | 4.98M | 5.49M | 6.26M |
Retained Earnings | -50.17M | -49.03M | -67.26M | -73.03M | -72.8M | -89.72M | -96.74M | -113.35M | -124.84M | -127.94M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -2.7M | -2.84M | -969K | -969K | -969K | -969K | -969K | -969K | -969K | -969K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CLGN Cash Flow Statement
CollPlant Biotechnologies Ltd. (CLGN) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -4.97M | -1.22M | -5.7M | -4.45M | 2.5M | -13.7M | -2.76M | -14.09M | -9.42M | -11.58M |
Operating CF Margin % | -1034.76% | -25.42% | -246.03% | -72.53% | 15.99% | -4581.27% | -25.21% | -2736.5% | -397.26% | - |
Operating CF Growth % | 1.16% | 75.49% | -368.61% | 21.95% | 156.19% | -647.7% | 79.83% | -410.06% | 33.17% | -99.49% |
Net Income | -6.05M | -6.25M | -11.16M | -5.77M | 237K | -16.93M | -7.02M | -16.61M | -11.49M | -13.13M |
Depreciation & Amortization | 230K | 342K | 539K | 660K | 773K | 1.08M | 1.1M | 1.04M | 912K | 878K |
Stock-Based Compensation | 956K | 1.43M | 1.13M | 1.67M | 1.62M | 2.17M | 1.94M | 1.72M | 0 | 818K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -502K | 4.03M | 2.39M | -870K | -284K | 588K | 216K | 21K | 904K | -567.83K |
Working Capital Changes | 401K | -773K | 1.41M | -141K | 155K | -611K | 1M | -262K | 254K | 429.82K |
Change in Receivables | -38K | -439K | 437K | -751K | 560K | 261K | 9K | -150K | 359K | 92.75K |
Change in Inventory | -59K | -653K | -74K | -374K | 181K | -312K | 749K | 280K | -129K | -4.39K |
Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -260K | 12.74K |
Cash from Investing | -127K | -832K | -1.46M | -519K | -31.56M | 28.92M | -1.16M | -539K | -27K | -26.09K |
Capital Expenditures | -127K | -832K | -1.49M | -437K | -1.43M | -1.27M | -954K | -483K | -28K | -26.1K |
CapEx % of Revenue | 26.46% | 17.38% | 64.32% | 7.12% | 9.13% | 426.09% | 8.71% | 93.79% | 1.18% | 6.71% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1K | 15 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 30K | -82K | -30.13M | 30.2M | -202K | -56K | 0 | 0 |
Cash from Financing | 9.11M | 2.75M | 5.41M | 4.46M | 38.76M | 1.87M | 1.11M | 9K | 3.1M | 4.87M |
Debt Issued (Net) | 0 | 46K | -20K | -24K | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.1M | 5.01M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 9.11M | 2.71M | 5.43M | 4.49M | 38.76M | 1.87M | 1.11M | 9K | 0 | -141.58K |
Net Change in Cash | 4.3M▲ 0% | 379K▼ 91.2% | -1.69M▼ 546.4% | -445K▲ 73.7% | 9.85M▲ 2313.0% | 16.49M▲ 67.4% | -3.19M▼ 119.3% | -14.77M▼ 362.9% | -6.21M▲ 58.0% | -6.39M▲ 0% |
Free Cash Flow | -5.09M▲ 0% | -2.05M▲ 59.8% | -7.19M▼ 251.1% | -4.89M▲ 32.1% | 1.07M▲ 122.0% | -14.97M▼ 1495.3% | -3.72M▲ 75.2% | -14.58M▼ 292.1% | -9.45M▲ 35.2% | -11.6M▲ 0% |
FCF Margin % | -1061.23% | -42.79% | -310.35% | -79.65% | 6.86% | -5007.36% | -33.92% | -2830.29% | -398.44% | -2982.55% |
FCF Growth % | 1.14% | 59.77% | -251.1% | 32.05% | 121.95% | -1495.34% | 75.17% | -292.14% | 35.19% | 6.56% |
FCF per Share | -1.91 | -0.47 | -1.44 | -0.71 | 0.09 | -1.36 | -0.33 | -1.27 | -0.77 | -0.84 |
FCF Conversion (FCF/Net Income) | 0.86x | 0.19x | 0.51x | 0.77x | 10.55x | 0.81x | 0.39x | 0.85x | 0.82x | 0.88x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 31K | 8K | 62K | 0 | 0 |
CLGN Key Ratios
CollPlant Biotechnologies Ltd. (CLGN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -293.56% | -169.51% | -252.36% | -134.83% | 0.96% | -43.73% | -23.16% | -79.46% | -117.56% | -160.28% |
Return on Invested Capital (ROIC) | -606.04% | -1016.06% | -337.49% | -99.43% | 0.24% | -62.37% | -108.72% | -273.48% | -226.22% | -282.07% |
Gross Margin | 32.85% | 64.99% | 18.94% | 43.65% | 87.18% | -393.65% | 71.78% | -417.09% | 26.32% | -319.28% |
Net Margin | -1209.56% | -130.5% | -481.62% | -94.09% | 1.52% | -5660.54% | -64.05% | -3225.05% | -484.56% | -3376.35% |
Debt / Equity | 1.39x | 0.01x | 0.89x | 0.76x | 0.08x | 0.09x | 0.11x | 0.23x | 0.47x | 0.54x |
Interest Coverage | -53.95x | -239.35x | -151.93x | -168.82x | 7.41x | -496.79x | -700.90x | -976.00x | -765.53x | -57.19x |
FCF Conversion | 0.86x | 0.19x | 0.51x | 0.77x | 10.55x | 0.81x | 0.39x | 0.85x | 0.82x | 0.88x |
Revenue Growth | 532.21% | 897.75% | -51.59% | 164.75% | 154.86% | -98.09% | 3565.22% | -95.3% | 360.39% | -84.26% |
Related:CLGN Dividend History·CLGN Revenue History·CLGN Price History·CLGN P/E History·CLGN Financial Ratios·CLGN Institutional Holders
CLGN Frequently Asked Questions
CollPlant Biotechnologies Ltd. (CLGN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
CollPlant Biotechnologies Ltd. (CLGN) reported $0.4M in revenue for fiscal year 2025.
CollPlant Biotechnologies Ltd. (CLGN) grew revenue by 360.4% over the past year. This is strong growth.
CollPlant Biotechnologies Ltd. (CLGN) reported a net loss of $13.1M for fiscal year 2025.
Dividend & Returns
CollPlant Biotechnologies Ltd. (CLGN) has a return on equity (ROE) of -117.6%. Negative ROE indicates the company is unprofitable.
CollPlant Biotechnologies Ltd. (CLGN) had negative free cash flow of $11.6M in fiscal year 2025, likely due to heavy capital investments.